Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) Non Operating Investment Income (2020 - 2025)

Historic Non Operating Investment Income for C4 Therapeutics (CCCC) over the last 6 years, with Q2 2025 value amounting to -$73000.0.

  • C4 Therapeutics' Non Operating Investment Income fell 2166.67% to -$73000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was -$495000.0, marking a year-over-year decrease of 33459.72%. This contributed to the annual value of $180000.0 for FY2024, which is 9551.12% down from last year.
  • Latest data reveals that C4 Therapeutics reported Non Operating Investment Income of -$73000.0 as of Q2 2025, which was down 2166.67% from -$10000.0 recorded in Q1 2025.
  • In the past 5 years, C4 Therapeutics' Non Operating Investment Income ranged from a high of $1.7 million in Q1 2023 and a low of -$2.9 million during Q1 2022
  • Over the past 5 years, C4 Therapeutics' median Non Operating Investment Income value was -$66500.0 (recorded in 2024), while the average stood at -$2388.9.
  • The largest annual percentage gain for C4 Therapeutics' Non Operating Investment Income in the last 5 years was 135000.0% (2021), contrasted with its biggest fall of 1250000.0% (2021).
  • Over the past 5 years, C4 Therapeutics' Non Operating Investment Income (Quarter) stood at -$620000.0 in 2021, then surged by 305.16% to $1.3 million in 2022, then plummeted by 38.92% to $777000.0 in 2023, then tumbled by 151.74% to -$402000.0 in 2024, then surged by 81.84% to -$73000.0 in 2025.
  • Its Non Operating Investment Income stands at -$73000.0 for Q2 2025, versus -$10000.0 for Q1 2025 and -$402000.0 for Q4 2024.